Jubilant Pharmova Limited

JUBLPHARMA

INE700A01033

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:19:35 2024-04-25 am EDT			5-day change	1st Jan Change
676.6 ^INR	-0.86%		-3.56%	+23.99%

05:10am	Jubilant Pharmova Subsidiary's Canadian Manufacturing Unit Gets Five Observations from US FDA	MT
Apr. 17	Jubilant Pharmova Unit Gets VAI Status for Roorkee, India Facility	MT

Jubilant Pharmova Limited Reports Earnings Results for the First Quarter Ended June 30, 2021

July 23, 2021 at 06:39 am EDT

Jubilant Pharmova Limited announced earnings results for the first quarter ended June 30, 2021. For the first quarter, the company announced total revenue was INR 16,385.4 million compared to INR 11,599.8 million a year ago. Net income was INR 1,605.6 million compared to INR 880.1 million a year ago. Basic earnings per share was INR 10.09 compared to INR 5.53 a year ago. Basic earnings per share from continuing operations was INR 10.09 compared to INR 2.23 a year ago.

Latest news about Jubilant Pharmova Limited

Jubilant Pharmova Subsidiary's Canadian Manufacturing Unit Gets Five Observations from US FDA	11:10pm	MT
Jubilant Pharmova Unit Gets VAI Status for Roorkee, India Facility	Apr. 17	MT
India's Jubilant Pharmova posts quarterly profit	Feb. 02	RE
Jubilant Pharmova Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 02	CI
Jubilant Ingrevia Redeems INR1 Billion at Maturity Date	Nov. 15	MT
Jubilant Pharmova Unit Gets US FDA's Approval for Technetium Sulfur Colloid Injection	Nov. 13	MT
Jubilant Pharmova Limited Announces the Resignation of Kumar Ramamurthi as Director and Whole-Time Director, Effective October 31, 2023	23-10-27	CI
Jubilant Pharmova Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	23-10-27	CI
Domino's India operator Jubilant beats Q2 profit estimates on cheaper launches	23-10-25	RE
Jubilant Pharmova Limited Recommends Dividend for the Year Ended March 31, 2023, Payable on or Before September 29, 2023	23-08-07	CI
Jubilant Pharmova Limited Recommends Dividend for the Financial Year Ended March 31, 2023	23-07-31	CI
Jubilant Pharmova's Consolidated Profit Plunges in Fiscal Q1	23-07-20	MT
Jubilant Pharmova Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-07-19	CI
Indian shares set for flat start ahead of key earnings	23-07-18	RE
Jubilant Pharmova Names Managing Director	23-05-30	MT
Late Rally Led by Consumer Goods, Financials Lifts Indian Equities to Close Higher	23-05-30	MT
Jubilant Pharmova CFO Steps Down	23-05-30	MT
Jubilant Pharmova Limited Announces Change in Directorate	23-05-30	CI
Jubilant Pharmova Limited Announces CFO Changes	23-05-30	CI
INDIA STOCKS-Indian shares rise to five-month high on improved global cues	23-05-30	RE
Jubilant Pharmova Limited Recommends Dividend for the Financial Year Ended March 31, 2023	23-05-29	CI
Jubilant Pharmova Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-05-29	CI
Jubilant Pharmanova's Canadian Arm Gets CA$24 Million Loan for Capacity Expansion	23-03-17	MT
Jubilant Pharmova Gets VAI from US FDA for API Manufacturing Facility in Karnataka, India	23-03-08	MT
Jubilant Pharmova Limited Appoints Shirish G. Belapure as Additional Director (Non-Executive, Independent)	23-03-08	CI

Chart Jubilant Pharmova Limited

Duration

Period

More charts

Company Profile

Jubilant Pharmova Limited is an India-based integrated pharmaceutical company. The Company's segments include Pharmaceuticals, Contract Research and Development Services and Proprietary Novel Drugs. The Pharmaceuticals segment, through wholly owned subsidiary Jubilant Pharma Limited, is engaged in manufacture and supply of active pharmaceutical ingredients (APIs), solid dosage formulations, radiopharmaceuticals, allergy therapy products and contract manufacturing of sterile injectables and non-sterile products through six manufacturing facilities in India, United States and Canada and a network of approximately 48 radio pharmacies in the United States. The Contract Research and Development Services segment provides drug discovery and development services as well as clinical data software and service solutions. The Proprietary Novel Drugs segment is a patient-focused biopharmaceutical business working to address unmet medical needs in oncology and autoimmune diseases.

Sector

Pharmaceuticals

Calendar

2024-05-30 - Q4 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
JUBILANT PHARMOVA LIMITED	+23.99%	1.3B
ELI LILLY AND COMPANY	+25.61%	660B
NOVO NORDISK A/S	+22.68%	562B
JOHNSON & JOHNSON	-5.24%	358B
MERCK & CO., INC.	+16.49%	322B
ABBVIE INC.	+8.28%	297B
ASTRAZENECA PLC	+13.64%	219B
ROCHE HOLDING AG	-9.49%	196B
NOVARTIS AG	+6.74%	199B
PFIZER, INC.	-8.75%	149B

Other Pharmaceuticals